Neurogene Inc. Operating Lease, Liability, Noncurrent
Neurogene Inc. (NGNE) had Operating Lease, Liability, Noncurrent of $5.32 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-11
- 2026-06-30: Operating Lease, Liability, Noncurrent $5.32M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $6.08M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $6.82M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $7.10M.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $5.32M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $6.08M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $6.82M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $7.10M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $7.82M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $8.61M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $9.40M 10-K · filed 2026-03-24 | |
| 2024-09-30 | $10.17M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $10.91M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $11.64M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $12.30M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $9.13M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $9.54M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $9.94M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $3.92M 10-K · filed 2024-03-18 | $10.32M 10-K · filed 2023-03-20 |
| 2022-09-30 | $10.68M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $11.03M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $11.37M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $11.70M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $12.00M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $12.30M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $12.61M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $11.31M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $11.35M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $10.20M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $10.18M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $447.00K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $205.00K 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $253.00K 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $292.00K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |